Please assess the completion status of the following clinical trial:

Trial Title: Epirubicin and Docetaxel in Treating Patients With Metastatic Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed adenocarcinoma of the prostate~* Meets 1 of the following criteria:~  * Measurable disease with any prostate-specific antigen (PSA) value~    * Unidimensionally measurable lesion ≥ 20 mm by conventional techniques OR ≥ 10 mm by spiral CT scan~   * Histologic confirmation required if measurable disease is confined to a solitary lesion~ * Non-measurable disease with PSA ≥ 5 ng/mL\*~    * The following are considered non-measurable disease:~      * Bone lesions~     * Pleural or pericardial effusion~     * Ascites~     * CNS lesions~     * Leptomeningeal disease~     * Irradiated lesions unless disease progression was documented after prior radiotherapy NOTE: \*Patients with PSA ≥ 5 ng/mL only are not eligible~* Progressive systemic disease despite ≥ 1 prior standard endocrine therapy with orchiectomy, luteinizing hormone-releasing hormone (LHRH) agonist, or diethylstilbestrol, as indicated by 1 of the following criteria:~  * Objective evidence of increase \> 20% in the sum of the longest diameters of target lesions from the time of maximal regression OR the appearance of 1 or more new lesions~ * One or more new lesions on bone scan secondary to prostate cancer AND PSA ≥ 5 ng/mL~ * Elevated PSA (≥ 5 ng/mL) with 2 consecutive increases from baseline (taken ≥ 1 week apart)~* Serum testosterone ≤ 50 ng/dL for patients without bilateral orchiectomy~  * Patients who have not had a bilateral orchiectomy should continue therapy with primary testicular androgen suppression (e.g., LHRH analogues)~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* ECOG 0-2~Life expectancy~* Not specified~Hematopoietic~* Granulocyte count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~Hepatic~* Meets 1 of the following criteria:~  * AST or ALT normal AND alkaline phosphatase ≤ 5 times upper limit of normal (ULN)~ * AST or ALT ≤ 1.5 times ULN AND alkaline phosphatase ≤ 2.5 times ULN~ * AST or ALT ≤ 5 times ULN AND alkaline phosphatase normal~* Bilirubin normal~Renal~* Creatinine ≤ 1.5 times ULN~Cardiovascular~* No uncontrolled high blood pressure~* No unstable angina~* No symptomatic congestive heart failure~* No myocardial infarction within the past 6 months~* No serious uncontrolled cardiac arrhythmia~* No New York Heart Association class III or IV heart disease~Other~* Fertile patients must use effective contraception during and for at least 3 months after study participation~* No peripheral neuropathy ≥ grade 2~* No prior severe hypersensitivity reaction to docetaxel or other drug formulated with polysorbate 80~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No concurrent filgrastim (G-CSF) or sargramostim (GM-CSF)~Chemotherapy~* No prior chemotherapy, including estramustine or suramin for prostate cancer~* No other concurrent chemotherapy~Endocrine therapy~* See Disease Characteristics~* At least 4 weeks since prior antiandrogen therapy~* No concurrent hormonal therapy except steroids for adrenal insufficiency, hormones for non-disease-related conditions (e.g., insulin for diabetes), or intermittent dexamethasone as an antiemetic~Radiotherapy~* See Disease Characteristics~* At least 4 weeks since prior radiotherapy~* At least 8 weeks since prior strontium chloride Sr 89 or samarium Sm 153 lexidronam pentasodium~* No concurrent palliative radiotherapy~Surgery~* See Disease Characteristics~* At least 4 weeks since prior surgery and recovered

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).